Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
| Status: | Enrolling by invitation |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 12/13/2018 |
| Start Date: | February 22, 2017 |
| End Date: | March 2019 |
This study aims to compare patient use of and satisfaction with community
pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication
therapy management (MTM) service. Pharmacist and patient outcome measures will be collected
by surveys, interviews, and review of pharmacy records.
pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication
therapy management (MTM) service. Pharmacist and patient outcome measures will be collected
by surveys, interviews, and review of pharmacy records.
This study aims to investigate the delivery of pharmacogenetic (PGx) testing alone or in
combination with Medication Therapy Management (MTM) in the community pharmacy setting in
order to assess and compare the two delivery models. Using a clust randomized trial, these
effects of these two models will be compared. Pharmacist and patient outcome measures will be
collected by survey, interviews, and review of pharmacy records. The investigators intend to
compare the effect of PGx alone and PGx with MTM from the pharmacy perspective (to assess
impact on workflow/operations) and patient perspective (to assess acceptance of testing,
understanding of results, medication adherence, and overall satisfaction with delivery
model). In the PGx only arm, pharmacists will offer PGx testing to patients who are
prescribed one of the 10 eligible drugs (aripiprazole, carisoprodol, celecoxib, citalopram,
clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin) and will return
results to the patient and physician with any recommendations for drug or dosage changes
based on results. In the PGx and MTM arm, pharmacists will offer PGx testing to patients
prescribed one of the 10 eligible drugs and provide two MTM sessions: one at the time of
testing, and one when results are returned. All patients will be surveyed before PGx testing
and 3 months after receiving results. Pharmacists will be surveyed prior to their
participation and following the conclusion of the study. Pharmacists will also conduct a
chart review of patients and document all interactions with enrolled patients and their
providers.
combination with Medication Therapy Management (MTM) in the community pharmacy setting in
order to assess and compare the two delivery models. Using a clust randomized trial, these
effects of these two models will be compared. Pharmacist and patient outcome measures will be
collected by survey, interviews, and review of pharmacy records. The investigators intend to
compare the effect of PGx alone and PGx with MTM from the pharmacy perspective (to assess
impact on workflow/operations) and patient perspective (to assess acceptance of testing,
understanding of results, medication adherence, and overall satisfaction with delivery
model). In the PGx only arm, pharmacists will offer PGx testing to patients who are
prescribed one of the 10 eligible drugs (aripiprazole, carisoprodol, celecoxib, citalopram,
clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin) and will return
results to the patient and physician with any recommendations for drug or dosage changes
based on results. In the PGx and MTM arm, pharmacists will offer PGx testing to patients
prescribed one of the 10 eligible drugs and provide two MTM sessions: one at the time of
testing, and one when results are returned. All patients will be surveyed before PGx testing
and 3 months after receiving results. Pharmacists will be surveyed prior to their
participation and following the conclusion of the study. Pharmacists will also conduct a
chart review of patients and document all interactions with enrolled patients and their
providers.
Inclusion Criteria:
- Pharmacist participants must be community pharmacists licensed and practicing in North
Carolina
- Patient participants must be prescribed one of the 10 eligible medications
(aripiprazole, carisoprodol, celecoxib, citalopram, clopidogrel, metoprolol,
nortriptyline, paroxetine, simvastatin, warfarin)
- Patient participants must be able to consent to participating and testing on their
own, and be able to read English
Exclusion Criteria:
- Patients who have previously undergone pharmacogenetic testing will not be eligible.
We found this trial at
1
site
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
